An Efficacy and Safety Study of DFN-02

Trial Profile

An Efficacy and Safety Study of DFN-02

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs DFN 02 (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Dr Reddys Laboratories
  • Most Recent Events

    • 28 Jun 2017 Results from this study published in an Aegis Therapeutics Media Release.
    • 07 Jun 2017 Primary endpoint has been met. (Proportion of patients who are pain-free at 2 hours postdose in the first double-blind treatment period), as reported in a Promius Pharma media release.
    • 07 Jun 2017 Results published in a Promius Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top